The heartbreak of psoriasis has one more heartbreak, as with many other drugs in the news of late, potential side effects are the news here.  BD 
South San Francisco, Calif.  –  April 8, 2009 –
Genentech, Inc. announced today a phased voluntary withdrawal of the psoriasis drug
Raptiva® (efalizumab) from the U.S. market. The company’s decision is based on the association of Raptiva with an increased risk of progressive multifocal leukoencephalopathy (more…)